ESR1 and breast cancer: Pre-clinical data show that BC cells harboring LBD ESR1 mutations display partial resistance to tamoxifen and fulvestrant in vitro, as higher doses of these agents are needed to elicit their anti-proliferative effect in cells carrying such mutations [22,28].